GlassScriptPhysician profile
Masroor Mustafa
NPI 1437182540
$1,110.14
in general payments reported to CMS, 2019-2025
12 companies · $283 in 2025
The $283 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $245 · 2021: $2.50 · 2022: $12.06 · 2023: $181 · 2024: $386 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $750 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.31 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $387.89 | 2020-2025 | |
| Glaxosmithkline, LLC. | $154.99 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Jazz Pharmaceuticals INC. | $139.07 | 2020-2025 | |
| Inspire Medical Systems, INC. | $138.84 | 2023-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Fisher & Paykel Healthcare INC | $69.26 | 2024-2025 | Fisher & Paykel Healthcare |
| Avadel Cns Pharmaceuticals, LLC | $37.91 | 2024 | Lumryz |
| Amgen INC. | $27.39 | 2025 | Tavneos |
| Insmed, INC. | $22.69 | 2025 | Arikayce |
| 3b Medical, INC. | $15.85 | 2023 | Luna |
| Phadia US INC. | $13.80 | 2024 | Immunocap |
| United Therapeutics Corporation | $2.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Masroor Mustafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.